Detalhe da pesquisa
1.
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
J Clin Oncol
; 40(32): 3750-3761, 2022 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35709415